Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
PHX Energy Q2 FY26 earnings rise 29% to $11 million; revenue climbs 7% to $178.9 million

PHX Energy Q2 FY26 earnings rise 29% to $11 million; revenue climbs 7% to $178.9 million

ReutersReuters2026/08/04 21:55
  • PHX Energy posted Q2 earnings of $11 million, rising 29%, with diluted EPS up 24% to $0.21.
  • Revenue climbed 7% to $178.9 million, marking the highest second-quarter level in the company’s history.
  • Adjusted EBITDA (non-GAAP) increased 20% to $33 million, lifting the margin to 18% from 16% a year earlier.
  • Record RSS activity accounted for 21% of consolidated operating days, with total operating days up 7% to 7,347.
  • Management flagged a Q3 industry uptick, plans to renew the NCIB, with the 2026 capex budget raised to $80 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PHX Energy Services Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041707PRIMZONEFULLFEED9803756) on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application

Adarx Pharmaceuticals Inc. has filed for an IPO in the United States to help fund the development of a pipeline of drugs aimed at treating various diseases by regulating gene expression.

智通财经2026/09/05 01:16
With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application